Aprea Therapeutics Announces Twice Daily (Bid) Dosing of Patients in Aboya-119 Clinical Trial of Atrn-119 to Potentially Optimize Clinical Outcomes and Strengthen Clinical Path Forward
Aprea Therapeutics宣佈在Atrn-119的Aboya-119臨床試驗中對患者進行每日兩次（買盤）給藥，以潛在地優化臨床結果並加強臨床前進路徑。
